Abstract
Aim:
To gain insight into the histopathological responses and molecular targets in the inhibition of growth of human gastric cancer treated with celecoxib (a cyclooxygenase [COX]-2 inhibitor) combined with octreotide.
Methods:
Seventy five patients with gastric cancer undergoing curative gastrectomy or extended resection were randomly divided into 3 groups. The apoptosis of tumor cells was measured by terminal deoxynucleotide transferase-mediated dUTP nick end-labeling (TUNEL) assay. Gastric cancer microvessel density (MVD) and the expression of COX-2 were evaluated by immunohistochemical staining. The expression of somatostatin receptor (SSTR)-2 was detected with the biomolecular interaction analysis system. The transcription of non-steroidal anti-inflammatory drug-activated gene (NAG)-1 was measured by RT-PCR.
Results:
Compared with the control and celecoxib groups, more necrosis in the combination group was observed. The apoptotic rate in the combination group (7.06%±0.67%) was significantly higher than that in the control group (6.23%±1.29%, P<0.05). The MVD decreased considerably in the combination group. The upregulation of NAG-1 was displayed both in the celecoxib and combination groups. The positive rate of SSTR-2 in gastric cancers treated with celecoxib (48%) was significantly higher than that of control group (12%) after surgery (P<0.05).
Conclusion:
Celecoxib combined with octreotide significantly promoted necrosis in gastric adenocarci-noma through the induction of apoptosis and the reduction of MVD. NAG-1 and SSTR-2 might be the molecular targets for celecoxib or octreotide.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM . Gastric adenocarcinoma: review and considerations for future directions. Ann Surg 2005; 241: 27–39.
Wohrer SS, Raderer M, Hejna M . Palliative chemotherapy for advanced gastric cancer. Ann Oncol 2004; 15: 1585–95.
Liu CL, Tang CW, Wang CH, Zhou XC . The effects of selective cyclooxygenase-2 inhibitors on the growth of gastric adeno-carcinoma. J West China Univ Med Sci 2003; 3: 372–5. Chinese.
Baek SJ, Wilson LC, Lee CH, Eling TE . Dual function of nonsteroidal anti-inflammatory drugs (NSAIDs): inhibition of cyclo-oxygenase and induction of NSAID-activated gene. J Pharmacol Exp Ther 2002; 301: 1126–31.
Uefuji K, Ichikura T, Mochizuki H . Expression of cyclo-oxygenase-2 in human gastric adenomas and adenocarcinomas. J Surg Oncol 2001; 76: 26–30.
Ohno R, Yoshinaga K, Fujita T, Hasegawa K, Iseki H, Tsunozaki H, et al. Depth of invasion parallels increased cyclooxygenase-2 levels in patients with gastric carcinoma. Cancer 2001; 91: 1876–81.
Maoret JJ, Anini Y, Rouyer-Fessard C, Gully D, Laburthe M . Neurotensin and a non-peptide neurotensin receptor antagonist control human colon cancer cell growth in cell culture and in cells xenografted into nude mice. Int J Cancer 1999; 80: 448–54.
Pollak MN, Schally AV . Mechanisms of antineoplastic action of somatostatin analogs. Proc Soc Exp Biol Med 1998; 217: 143–52.
Tang C, Wang C, Tang L . Effects of combined octreotide and aspirin on the growth of gastric cancer. Chin Med J (Engl) 2003; 116: 373–7.
Pinski J, Halmos G, Yano T, Szepeshazi K, Qin Y, Ertl T, et al. Inhibition of growth of MKN45 human gastric-carcinoma xenografts in nude mice by treatment with bombesin/gastrin-releasing-peptide antagonist (RC-3095) and somatostatin analogue RC-160. Int J Cancer 1994; 57: 574–80.
Reisine T, Bell GI . Molecular biology of somatostatin receptors. Endocr Rev 1995; 16: 427–42.
Kwon KS, Chae HJ . Sodium salicylate inhibits expression of COX-2 through suppression of ERK and subsequent NF-kappaB activation in rat ventricular cardiomyocytes. Arch Pharm Res 2003; 26: 545–53.
Tang CW, Liu CL, Zhou XC, Wang CH . Enhanced inhibitive effects of combination of rofecoxib and octreotide on the growth of human gastric cancer. Int J Cancer 2004; 112: 470–4.
Gavrieli Y, Sherman Y, Beb-Sasson SA . Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992; 119: 493–501.
Hasan J, Byers R, Jayson GC . Intra-tumoural microvessel density in human solid tumours. Br J Cancer 2002; 86: 1566–77.
Dhar DK, Wang TC, Tabara H, Tonomoto Y, Maruyama R, Tachibana M, et al. Expression of trefoil factor family members correlates with patient prognosis and neoangiogenesis. Clin Cancer Res 2005; 11: 6472–8.
Casper D, Bukhtiyarova M, Springman EB . A Biacore biosensor method for detailed kinetic binding analysis of small molecule inhibitors of p38alpha mitogen-activated protein kinase. Anal Biochem 2004; 325: 126–36.
Sarbia M, Becker KF, Hofler H . Pathology of upper gastrointestinal malignancies. Semin Oncol 2004; 31: 465–75.
Jazowiecka-Rakus J, Jarosz M, Kozlowska D, Sochanik A, Szala S . Combination of vasostatin and cyclophosphamide in the therapy of murine melanoma tumors. Acta Biochim Pol 2007; 54: 125–33.
Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma — 2nd English Edition. Gastric Cancer 1998; 1: 10–24.
Diasio RB, Fourie J . Targeting the epidermal growth factor receptor in the treatment of colorectal cancer: state of the art. Drugs 2006; 66: 1441–63.
Baek SJ, Kim JS, Moore SM, Lee SH, Martinez J, Eling TE . Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR-1, which results in the up-regulation of NAG-1, an antitumorigenic protein. Mol Pharmacol 2005; 67: 356–64.
Hu C, Yi C, Hao Z, Cao S, Li H, Shao X, et al. The effect of somatostatin and SSTR3 on proliferation and apoptosis of gastric cancer cells. Cancer Biol Ther 2004; 3: 726–30.
Kouroumalis EA . Octreotide for cancer of the liver and biliary tree. Chemotherapy 2001; 47 Suppl 2: 150–61.
Wang CH, Tang CW, Liu CL, Tang LP . Inhibitory effect of octreotide on gastric cancer growth via MAPK pathway. World J Gastroenterol 2003; 9: 1904–8.
Liu C, Tang C, Zhou X, Wang C . Enhanced inhibitive effects of combination of rofecoxib and octreotide on the growth of human gastric cancer. Basic Med Sci Clin 2004; 24: 277–81. Chinese.
Gajraj NM . Cyclooxygenase-2 inhibitors. Anesth Analg 2003; 96: 1720–38.
Riendeau D, Percival MD, Brideau C, Charleson S, Dube D, Ethier D, et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001; 296: 558–66.
Macdonald JS . Clinical overview: adjuvant therapy of gastrointestinal cancer. Cancer Chemother Pharmacol 2004; 54 Suppl 1: S4–11.
Lindsey H . Preoperative chemoradiotherapy shows promise in gastric cancer. Lancet Oncol 2004; 5: 519.
Author information
Authors and Affiliations
Corresponding author
Additional information
This work was supported by a grant from National Natural Science Foundation of China (No 30170418) and the Key Program from the Department of Science and Technology of Sichuan Province, China (No 02SG011-066).
Rights and permissions
About this article
Cite this article
Huang, Mt., Chen, Zx., Wei, B. et al. Preoperative growth inhibition of human gastric adenocarcinoma treated with a combination of celecoxib and octreotide. Acta Pharmacol Sin 28, 1842–1850 (2007). https://doi.org/10.1111/j.1745-7254.2007.00652.x
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1111/j.1745-7254.2007.00652.x
Keywords
This article is cited by
-
Preoperative diagnosis of metastatic lymph nodes by CT-histopathologic matching analysis in gastric adenocarcinoma using dual-layer spectral detector CT
European Radiology (2023)
-
Anticancer Effect of Celecoxib via COX-2 Dependent and Independent Mechanisms in Human Gastric Cancers Cells
Digestive Diseases and Sciences (2009)
